ABBV-453
- Generic Name
- ABBV-453
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Phase 1
Not yet recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 130
- Registration Number
- NCT06953960
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Phase 1
Recruiting
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 80
- Registration Number
- NCT06291220
- Locations
- 🇩🇪
Universitaetsklinikum Ulm /ID# 263148, Ulm, Baden-Wuerttemberg, Germany
🇺🇸City of Hope /ID# 253904, Duarte, California, United States
🇺🇸City of Hope Orange County Lennar Foundation Cancer Center /ID# 267158, Irvine, California, United States
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
Phase 1
Active, not recruiting
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 34
- Registration Number
- NCT05308654
- Locations
- 🇺🇸
Tulane University School of Medicine /ID# 244854, New Orleans, Louisiana, United States
🇺🇸American Oncology Partners of Maryland /ID# 244858, Bethesda, Maryland, United States
🇺🇸Atrium Health Levine Cancer Institute /ID# 243420, Charlotte, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath